加拿大三级医疗中心2000至2013年曲霉Fumigati组临床分离株唑类耐药率及机制
该研究对蒙特利尔一家医院14年间收集的807例患者共999株Fumigati组曲霉进行唑类耐药筛查,并利用基因组测序、三维建模和表型外排泵试验探究耐药机制。总体唑类耐药率低(4/807患者,0.5%),其中1株烟曲霉敏感严格种耐药由外排泵介导,3例患者定植或感染唑类耐药隐匿Fumigati种。结论认为该地区唑类耐药罕见,当前主要由隐匿Fumigati种驱动,需持续监测。
要点
- 该地区Fumigati组曲霉唑类耐药率低,807例患者中仅4例(0.5%)耐药。
- 耐药可由外排泵介导(烟曲霉及A. turcosus),而A. lentulus和A. thermomutatus未见外排泵介导。
- 隐匿Fumigati种是当前唑类耐药的主要来源,需持续监测。
核心结论
- 该地区Fumigati组曲霉唑类耐药罕见,当前耐药主要由隐匿Fumigati种驱动,需持续监测耐药出现。
研究设计与样本
- 回顾性收集加拿大蒙特利尔一家医院2000至2013年共14年的Fumigati组曲霉999株,来自807例患者,进行唑类耐药筛查。
- 采用基因组测序、三维建模和表型外排泵试验研究耐药机制。
主要发现
- 总体唑类耐药为4/807患者(0.5%)。
- 1株烟曲霉敏感严格种分离自肺曲霉病患者,显示外排泵介导的耐药。
- 3例患者定植或感染唑类耐药隐匿Fumigati种,分别为Aspergillus thermomutatus、Aspergillus lentulus和Aspergillus turcosus各1例。
- A. turcosus分离株的唑类耐药为外排泵介导,而A. lentulus和A. thermomutatus分离株未见外排泵介导。
临床怎么用
- 在唑类耐药低流行地区,临床仍需关注隐匿Fumigati种引起的耐药,尤其对唑类治疗失败者。
- 对Fumigati组曲霉临床分离株应继续开展唑类耐药监测,并考虑外排泵机制。
局限性
- 研究为单中心14年回顾性收集,仅基于加拿大蒙特利尔一家医院的数据。
- 耐药株数量少(4例患者),机制结论的普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Azole resistance among Aspergillus fumigatus isolates is a growing concern worldwide. Induction of mutations during azole therapy, environment-acquired mutations caused by azole fungicides and intrinsic resistance of cryptic Fumigati species all contribute to the burden of resistance. However, there is a lack of data in Canada on this emerging threat. METHODS: To gain insights into the magnitude and mechanisms of resistance, a 14 year collection of Aspergillus section Fumigati comprising 999 isolates from 807 patients at a Montreal hospital was screened for azole resistance, and resistance mechanisms were investigated with the combined use of genome sequencing, 3D modelling and phenotypic efflux pump assays. RESULTS: Overall azole resistance was low (4/807 patients; 0.5%). A single azole-resistant A. fumigatus sensu stricto strain, isolated from a patient with pulmonary aspergillosis, displayed efflux-pump-mediated resistance. Three patients were colonized or infected with azole-resistant cryptic Fumigati species (one Aspergillus thermomutatus, one Aspergillus lentulus and one Aspergillus turcosus). Evidence is presented that azole resistance is efflux-pump-mediated in the A. turcosus isolate, but not in the A. lentulus and A. thermomutatus isolates. CONCLUSIONS: Azole resistance is rare in our geographic area and currently driven by cryptic Fumigati species. Continued surveillance of emergence of resistance is warranted.
引用
- Parent-Michaud M, Dufresne PJ, Fournier E, et al. Prevalence and mechanisms of azole resistance in clinical isolates of Aspergillus section Fumigati species in a Canadian tertiary care centre, 2000 to 2013. J Antimicrob Chemother. 2020. PMID: 31891387. doi:10.1093/jac/dkz534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。